» Articles » PMID: 27095008

Persistently Active Disease is Common in Patients with Rheumatoid Arthritis, Particularly in Women: a Long-term Inception Cohort Study

Overview
Publisher Informa Healthcare
Specialty Rheumatology
Date 2016 Apr 21
PMID 27095008
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Despite improved treatment strategies for rheumatoid arthritis (RA), some patients do not respond satisfactorily. The aim of this study was to investigate the course and outcome of early RA diagnosed during the 1990s and followed for 8 years with a focus on those who did not respond well to treatment.

Method: This study included 640 patients (66% women) who were enrolled in the BARFOT (Better Anti-Rheumatic PharmacOTherapy) RA inception cohort between the years 1993 and 1999. The 28-joint count Disease Activity Score (DAS28) < 2.6 criteria were used to assess remission. Persistent disease (PD) was defined as absence of remission at all predefined follow-up visits at 1, 2, 5, and 8 years. Function was assessed by Health Assessment Questionnaire (HAQ) and Signals of Functional Impairment (SOFI) scores and radiological joint damage by the Sharp/van der Heijde score (SHS).

Results: Of the 640 patients, 214 (37%) had PD (43% of the women and 25% of the men). Over the 8 years of follow-up, patients with PD had significantly worse mean values for patient's global health measured on a visual analogue scale (VAS patGH), VAS pain, HAQ, SOFI, and SHS compared with those in the non-PD group. Multivariate logistic regression analyses revealed that female gender, current smoking, disease activity at baseline, and absence of remission at 6 months independently predicted PD.

Conclusions: Of the patients who entered the early RA inception cohort, 37% suffered a PD course over 8 years. The consequences of PD with regard to general health, pain, function, and joint damage were considerable. Of note, PD was more common in women than in men.

Citing Articles

Aberrant immunity in the oral cavity-a link with rheumatoid arthritis?.

Malcolm J, Culshaw S Front Oral Health. 2024; 5:1430886.

PMID: 38948089 PMC: 11211539. DOI: 10.3389/froh.2024.1430886.


A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with....

Cohen S, Beebe J, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M Arthritis Res Ther. 2024; 26(1):117.

PMID: 38845046 PMC: 11155132. DOI: 10.1186/s13075-024-03337-2.


Tailoring Rheumatoid Arthritis Treatment through a Sex and Gender Lens.

Carmona L, Aurrecoechea E, Garcia de Yebenes M J Clin Med. 2024; 13(1).

PMID: 38202062 PMC: 10779667. DOI: 10.3390/jcm13010055.


Trends in Incidence of Chronic Heart Failure in Patients With Rheumatoid Arthritis: A Population-Based Study Validating Different Heart Failure Definitions.

Myasoedova E, Kurmann R, Achenbach S, Wright K, Arment C, Dunlay S J Rheumatol. 2023; 50(7):881-888.

PMID: 36921969 PMC: 10330020. DOI: 10.3899/jrheum.221170.


Novel Compound Q-1 Alleviates Type II Collagen-Induced Arthritis in Rats through the NF-B Pathway.

Xu T, Guo J, Wu S, Wang Y, Liu X, Qian H Evid Based Complement Alternat Med. 2021; 2021:6627290.

PMID: 34367306 PMC: 8339345. DOI: 10.1155/2021/6627290.